Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | LATS1 | O95835 | 1/20 | 0.53 |
| ▸ | GBA1 | P04062 | 8/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609102 | 0.89 | LATS1 (0.62) | TSHRALDH1A1HPGDLMNALATS1 | |
| SCHEMBL7606434 | 0.87 | CYP1A2 (0.54) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7609072 | 0.86 | ALDH1A1 (0.58) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7609133 | 0.86 | LMNA (0.53) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7611890 | 0.85 | ALDH1A1 (0.55) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7613450 | 0.85 | PDE5A (0.65) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7610140 | 0.84 | ALDH1A1 (0.60) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7611406 | 0.84 | GBA1 (0.62) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7604753 | 0.83 | LMNA (0.57) | CYP1A2CYP3A4TSHRCLK4ALDH1A1 | |
| SCHEMBL7611549 | 0.83 | ALDH1A1 (0.59) | ALDH1A1HPGDLMNALATS1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | CYP1A2 1452/4885CYP3A4 834/4885TSHR 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.